Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer.

ABSTRACT:

Purpose

The PI3K/Akt/mTOR pathway is activated in the majority of pancreatic cancers, and inhibition of this pathway has antitumor effects in preclinical studies. We performed a multi-institutional, single-arm, phase II study of RAD001(everolimus), an oral inhibitor of mTOR, in patients who experienced treatment failure on first-line therapy with gemcitabine.

Patients and methods

Thirty-three patients with gemcitabine-refractory, metastatic pancreatic cancer were treated continuously with RAD001 at 10 mg daily. Prior treatment with fluorouracil in the perioperative setting was allowed. Patients were observed for toxicity, treatment response, and survival.

Results

Treatment with single-agent RAD001 was well-tolerated; the most common adverse events were mild hyperglyce

SUBMITTER: Wolpin BM 

PROVIDER: S-EPMC2645085 | biostudies-literature | 2009 Jan

REPOSITORIES: biostudies-literature